Chest
Original Research: AsthmaThe Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol
Section snippets
Patient Selection
Male and female subjects aged ≥ 12 years were eligible if they had a diagnosis of asthma (per investigator clinical judgement) and were currently receiving a prescription asthma medication. However, subjects could not have previously used inhaled long-acting β2-agonists. Concurrent use of other prescription asthma medication(s) was permitted. Exclusion criteria included pregnancy and/or lactation, or any significant systemic disease that in the opinion of the investigator may place a subject at
Results
There were 26,355 subjects randomized to study treatment. Demographic characteristics and asthma history were similar between treatment groups and are summarized in Tables 1 ,Table 2. In the previous 12 months, asthma emergency department (ED) visits and hospitalizations were reported by 26% and 8% of all subjects, respectively, while at least weekly symptoms of nocturnal asthma were reported by approximately 61% of all subjects. Baseline ICS use was reported by 47% of the overall population,
Total Population
The primary and secondary end point results are shown in Table 4. For the primary end point, there were no significant differences between treatment groups in the number of subjects with respiratory-related death or life-threatening experiences over the 28-week treatment period. There were small, but statistically significant differences between salmeterol and placebo for secondary end points associated with asthma-related and respiratory-related deaths and combined asthma-related death or
Kaplan-Meier Survival Analysis
Log-rank tests found no significant differences for time to primary end point, time to withdrawal related to a medical condition other than asthma, time to all-cause death, or time to first all-cause hospitalization (data not shown). Figures 3, 4 show that there were significant increases in time to withdrawal due to worsening asthma (p < 0.001), and time to withdrawal not related to a medical condition (p = 0.016) for salmeterol compared with placebo.
Adverse Events
Overall, 1,093 subjects (4% in each treatment group) had serious adverse events during the study. The most common serious adverse events, which occurred in 2% of all subjects, were events classified as lower respiratory tract in nature. All other serious adverse events occurred at an incidence of < 1%. Based on Kaplan-Meier analyses, there were statistically significant differences between the treatment groups for time to first serious adverse event causing discontinuation (salmeterol survival
Discussion
This randomized, double-blind, clinical trial was planned for 60,000 subjects, or 238 primary events, but was terminated following a planned interim analysis when approximately one half of the subjects were enrolled, subsequently providing 86 primary events. Predefined criteria for study termination were not met at the interim analysis. However, the study was terminated by GlaxoSmithKline due to preliminary findings in African Americans and difficulties in enrollment.
The results in the total
References (20)
- et al.
Reducing disparities in asthma care: priorities for research; National Heart, Lung, and Blood Institute workshop report
J Allergy Clin Immunol
(2002) - et al.
Prescribed fenoterol and death from asthma in New Zealand, 1981–83: a case-control study
Lancet
(1989) - et al.
Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients
J Clin Epidemiol
(1996) - et al.
How and by whom care is delivered influences anti-inflammatory use in asthma: results of a national population survey
J Allergy Clin Immunol
(2003) - et al.
Surveillance for Asthma-United States, 1980–1999
MMWR Morb Mortal Wkly Rep
(2002) - et al.
Investigation into use of drugs preceding death from asthma
BMJ
(1968) Asthma mortality: why the United States was spared an epidemic of deaths due to asthma
Am Rev Respir Dis
(1972)- et al.
Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977–1981
Thorax
(1990) - et al.
Prescribed fenoterol and death from asthma in New Zealand 1981–7: a further case-control study
Thorax
(1991) - et al.
Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol
Am J Respir Crit Care Med
(1998)
Cited by (1071)
The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today
2024, Journal of Allergy and Clinical Immunology: In PracticeBoxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making
2022, Journal of Allergy and Clinical Immunology: In PracticeAdvances in Evaluation and Treatment of Severe Asthma (Part One)
2022, Medical Clinics of North AmericaEvaluation and Management of Asthma and Chronic Obstructive Pulmonary Disease Exacerbation in the Emergency Department
2022, Emergency Medicine Clinics of North America
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
Dr. Nelson is a consultant, speaker, and recipient of research grants from GlaxoSmithKline, and was also a member of the MMRC for this study. Dr. Weiss is a consultant for GlaxoSmithKline, and was also a member of the MMRC for this study. Dr. Bleecker is a consultant, speaker, and recipient of research grants from GlaxoSmithKline, and was a member of the MMRC for this study. Mr. Yancey is an employee of GlaxoSmithKline. Dr. Dorinsky is an employee of GlaxoSmithKline.
These data were presented in part at the American College of Chest Physicians Conference in Orlando, FL, October 25–30, 2003.